H3 Pharma Plans First Quarter Response To Sanvar IR "Approvable" Letter

FDA letter requests additional supportive efficacy data and further information related to manufacturing. H3 Pharma expects that the results from a recently completed Phase III study will address the issues cited in the letter.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet